Cite

HARVARD Citation

    Lameijer, M. et al. (2018). Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nature biomedical engineering. pp. 279-292. [Online]. 
  
Back to record